Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Sebastian Schulte-Eistrup"'
Autor:
Philipp Mewes, Jürgen R. Sindermann, Nils Reiss, Frerk Müller-von Aschwege, Jan-Dirk Hoffmann, Sebastian Schulte-Eistrup, Jan D. Schmitto, Jenny I. Glitza, Thomas Schmidt
Publikováno v:
Artificial Organs. 44:248-256
For the success of the treatment with a left ventricular assist device (LVAD), both adequate self-management by the patient and an optimum level of support from the implanting hospital are crucial. A smartphone application has recently been developed
Autor:
Hermann Reichenspurner, L. Christian Napp, Arjang Ruhparwar, Evgenij V. Potapov, Nadja Mayer-Wingert, Bastian Schmack, Christoph Benk, David Schibilsky, Sebastian Schulte-Eistrup, Frank Spillmann, Alexander M. Bernhardt, Carsten Tschöpe, Jan D. Schmitto, Nicolas Doll
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 40(8)
Background The Abiomed Impella 5.5 (Danvers, MA) is a newly developed axial flow transaortic cardiac support device mounted on a 9 Fr steering catheter with a 21 Fr pump cannula . Impella 5.5 is intended for longer use and was approved for 30 days in
Autor:
Sebastian Schulte-Eistrup, Meike Hannig, Thomas Schmidt, Stephanie Mommertz, Birna Bjarnason-Wehrens, Nils Reiss, Detlev Willemsen
Publikováno v:
Artificial Organs. 42:686-694
Following implantation of a left ventricular assist device (LVAD), acceptable functional performance is now being achieved; however, peak VO2 and peak work load (watts) remain considerably limited. Maximum physical capacity is essentially dependent o
Autor:
Thomas Schmidt, Nils Reiss, Birna Bjarnason-Wehrens, Detlev Willemsen, Jan D. Schmitto, Ezin Deniz, Sebastian Schulte-Eistrup, Petra Bartsch
Publikováno v:
Artificial Organs. 42:22-30
Adequate physical and functional performance is an important prerequisite for renewed participation and integration in self-determined private and (where appropriate) professional lives following left ventricular assist device (LVAD) implantation. Du
Autor:
Michael Billion, Thomas Schmidt, Jan D. Schmitto, Henning Warnecke, Sebastian Schulte-Eistrup, Nils Reiss
Publikováno v:
Operative Techniques in Thoracic and Cardiovascular Surgery. 22:186-197
Because of the decreasing availability of donor hearts and the simultaneous increase in patients with terminal heart failure, the implantation of a left ventricular assist device has become the only reasonable alternative to heart transplantation. Th
Autor:
Nils, Reiss, Kirby Kristin, Wegner, Jan-Dirk, Hoffmann, Sebastian, Schulte Eistrup, Udo, Boeken, Michiel, Morshuis, Thomas, Schmidt
Publikováno v:
Studies in health technology and informatics. 260
E-health, especially telemedicine, has undergone a remarkably dynamic development over the last decade. Most experience is currently in the field of telemedical care for heart failure (HF) patients. However, HF patients with an implanted left-ventric
Autor:
Sebastian Schulte-Eistrup, Detlev Willemsen, Jürgen R. Sindermann, Stephanie Mommertz, Thomas Schmidt, Nils Reiss, Hans-Georg Predel, Birna Bjarnason-Wehrens
Publikováno v:
The International journal of artificial organs. 42(4)
Following implantation of a left ventricular assist device, the build-up and long-term maintenance of adequate exercise capacity and functional performance become crucial. The aim of this study was to observe the development of exercise-related value
Autor:
Sebastian Schulte-Eistrup, D. Willemsen, Nils Reiss, T. Schmidt, M. Altesellmeier, S. Mommertz
Publikováno v:
Herz. 41:507-513
In the course of time implantation of left ventricular assist devices (LVAD) has become an alternative to heart transplantation due to the enormous technical developments and miniaturization of these systems. Following implantation most patients show
Autor:
H. Reichenspurner, Sebastian Schulte-Eistrup, Alexander M. Bernhardt, David Schibilsky, Arjang Ruhparwar, Evgenij Potapov, J.D. Schmitto
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S99
Purpose The Abiomed Impella 5.5 (Danvers, MA), is a newly developed axial flow trans-aortic cardiac support device mounted on a 9 Fr steering catheter with a 21 Fr pump cannula. The Impella 5.5 is intended for longer use and received in 2018 CE mark
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S202
Purpose Driveline infections (DLI), the main entity of VAD specific infections, in chronic mechanical circulatory support (MCS) increase with extended support times and contribute significantly to mortality and morbidity. The incidence of DLIs remain